Bruised but stand­ing, Sy­ros braves its way through a $50M IPO

7 years ago
R&D

No­var­tis shoots for ear­ly OK of a ‘break­through’ blood can­cer drug af­ter re­vers­ing or­gan dam­age in tri­al

7 years ago
R&D
Pharma

The biotech IPO feast flags as in­vestors lose their ap­petite for R&D risk

7 years ago
Financing

What PDU­FA date? Clo­vis shares surge as PARPs get trendy on Wall Street

7 years ago
R&D

Neoanti­gens beck­on Mer­ck in­to a $200M can­cer col­lab­o­ra­tion with Mod­er­na

7 years ago
R&D

Gale­na im­plodes as tri­al mon­i­tors call a halt to a failed PhI­II can­cer study

7 years ago
R&D

Tesaro rock­ets up af­ter PARP in­hibitor aces PhI­II study and R&D ri­val­ry in­ten­si­fies

7 years ago
R&D

Es­pe­ri­on tanks on warn­ing that the road to an FDA de­ci­sion could be much, much longer than they thought

7 years ago
R&D

Two flops in two weeks for Mar­i­nus Phar­ma­ceu­ti­cal­s' ganax­olone 

7 years ago
R&D

Trou­bled In­fin­i­ty ax­es 100 staffers, shut­ters tri­als and re­wards top ex­ecs af­ter Ab­b­Vie walks away from deal

7 years ago
Pharma

In lat­est set­back for stem cell sec­tor, Celyad fails PhI­II— and the biotech claims a vic­to­ry

7 years ago
R&D

No­var­tis inks a $2.5B bis­pe­cif­ic can­cer drug de­vel­op­ment al­liance with Xen­cor

7 years ago
R&D

Reg­u­lus craters af­ter FDA slaps a hold on hep C RNA drug fol­low­ing 2nd case of jaun­dice

7 years ago
Pharma

Third time the charm? An­a­lyst says a mar­ket­ing de­ci­sion is “im­mi­nent” for Sarep­ta’s Duchenne drug eteplirsen

7 years ago
R&D
Pharma

Bris­tol-My­ers’ nivolum­ab grabs its sixth break­through des­ig­na­tion as new links to au­toim­mune dis­eases creep up

7 years ago
Pharma

GW Phar­ma’s ral­ly rolls on as cannabi­noid drug scores again in PhI­II Epid­i­olex an­ti-con­vul­sive study

7 years ago
R&D

The Zer­houni rule: “Every com­pa­ny that ac­quires a plat­form com­pa­ny kills it.”

7 years ago
Bioregnum
Opinion

Scor­ing the 5 top phase III drugs in the glob­al pipeline

7 years ago
R&D
Pharma

IPO bound? CRISPR Ther­a­peu­tics ups B round to a cool $140M

7 years ago
Financing
Pharma

Medi­va­tion to Sanofi (in trans­la­tion): You don't know beans about can­cer drug de­vel­op­ment(!)

7 years ago
Pharma

What’s ahead for UK biotechs in the wake of Brex­it? It's not a pret­ty pic­ture

7 years ago
Pharma

These 300(+) Biotech Twit­ter cit­i­zens are the quick­est to tweet news

7 years ago
Bioregnum
Special

VC gi­ant NEA backs an up­start’s plan to tack­le neu­rode­gen­er­a­tion

7 years ago
Pharma

Ebo­la! Zi­ka! ATM! In­ovio CEO Kim called out for gam­ing pan­dem­ic pan­ic

7 years ago
People
Pharma
First page Previous page 697698699700701 Next page Last page